$
0.000
0.000(0.000%)
  • Overview
  • Forecast
  • Valuation

XBIO Relative Valuation

XBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XBIO is overvalued; if below, it's undervalued.

Historical Valuation

No Data

Competitors Valuation Multiple

The average P/S ratio for XBIO's competitors is 0.74, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO) exhibits a P/S ratio of 1.67, which is 125.32% above the industry average. Given its robust revenue growth of 16.14%, this premium appears unsustainable.

FAQ

arrow icon

Is Xenetic Biosciences Inc (XBIO) currently overvalued or undervalued?

Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.67 is considered Fairly compared with the five-year average of 9.95. The fair price of Xenetic Biosciences Inc (XBIO) is between 0.39 to 28.01 according to relative valuation methord.
arrow icon

What is Xenetic Biosciences Inc (XBIO) fair value?

arrow icon

How does XBIO's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Xenetic Biosciences Inc (XBIO) as of May 20 2025?

arrow icon

What is the current FCF Yield for Xenetic Biosciences Inc (XBIO) as of May 20 2025?

arrow icon

What is the current Forward P/E ratio for Xenetic Biosciences Inc (XBIO) as of May 20 2025?

arrow icon

What is the current Forward P/S ratio for Xenetic Biosciences Inc (XBIO) as of May 20 2025?